vs
Side-by-side financial comparison of Great Lakes Dredge & Dock CORP (GLDD) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($346.4M vs $256.5M, roughly 1.4× Great Lakes Dredge & Dock CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 4.9%, a 23.2% gap on every dollar of revenue. On growth, Great Lakes Dredge & Dock CORP posted the faster year-over-year revenue change (26.5% vs 4.8%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $50.3M). Over the past eight quarters, Great Lakes Dredge & Dock CORP's revenue compounded faster (13.6% CAGR vs 1.5%).
Great Lakes Dredge and Dock Company is an American company providing construction services in dredging and land reclamation, currently the largest such provider in the United States. GLD&D operates primarily in the United States but conducts one-quarter of its business overseas. The company was based in Oak Brook, Illinois, but in October 2020 relocated its corporate headquarters to Houston, Texas.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
GLDD vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $256.5M | $346.4M |
| Net Profit | $12.6M | $97.3M |
| Gross Margin | 20.9% | 57.2% |
| Operating Margin | 12.7% | 36.1% |
| Net Margin | 4.9% | 28.1% |
| Revenue YoY | 26.5% | 4.8% |
| Net Profit YoY | -35.9% | — |
| EPS (diluted) | $0.19 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | $256.5M | $339.0M | ||
| Q3 25 | $195.2M | $327.3M | ||
| Q2 25 | $193.8M | $321.4M | ||
| Q1 25 | $242.9M | $330.6M | ||
| Q4 24 | $202.8M | $348.5M | ||
| Q3 24 | $191.2M | $345.5M | ||
| Q2 24 | $170.1M | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $12.6M | $44.7M | ||
| Q3 25 | $17.7M | $38.7M | ||
| Q2 25 | $9.7M | $34.0M | ||
| Q1 25 | $33.4M | $58.0M | ||
| Q4 24 | $19.7M | $37.5M | ||
| Q3 24 | $8.9M | $33.8M | ||
| Q2 24 | $7.7M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | 20.9% | 59.7% | ||
| Q3 25 | 22.4% | 59.5% | ||
| Q2 25 | 18.9% | 59.8% | ||
| Q1 25 | 28.6% | 58.4% | ||
| Q4 24 | 24.1% | 55.5% | ||
| Q3 24 | 19.0% | 54.2% | ||
| Q2 24 | 17.5% | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 12.7% | 19.9% | ||
| Q3 25 | 14.4% | 17.9% | ||
| Q2 25 | 8.8% | 16.8% | ||
| Q1 25 | 20.6% | 21.6% | ||
| Q4 24 | 14.8% | 16.9% | ||
| Q3 24 | 8.7% | 15.0% | ||
| Q2 24 | 8.6% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 4.9% | 13.2% | ||
| Q3 25 | 9.1% | 11.8% | ||
| Q2 25 | 5.0% | 10.6% | ||
| Q1 25 | 13.8% | 17.5% | ||
| Q4 24 | 9.7% | 10.8% | ||
| Q3 24 | 4.6% | 9.8% | ||
| Q2 24 | 4.5% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.19 | $0.95 | ||
| Q3 25 | $0.26 | $0.81 | ||
| Q2 25 | $0.14 | $0.70 | ||
| Q1 25 | $0.49 | $1.17 | ||
| Q4 24 | $0.29 | $0.74 | ||
| Q3 24 | $0.13 | $0.66 | ||
| Q2 24 | $0.11 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.4M | $245.4M |
| Total DebtLower is stronger | $378.2M | $1.2B |
| Stockholders' EquityBook value | $517.1M | $796.3M |
| Total Assets | $1.3B | $2.4B |
| Debt / EquityLower = less leverage | 0.73× | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | $13.4M | $363.4M | ||
| Q3 25 | $12.7M | $296.4M | ||
| Q2 25 | $2.9M | $292.9M | ||
| Q1 25 | $11.3M | $306.8M | ||
| Q4 24 | $10.2M | $320.8M | ||
| Q3 24 | $12.0M | $299.3M | ||
| Q2 24 | $23.1M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $378.2M | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $448.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | $517.1M | $911.5M | ||
| Q3 25 | $502.1M | $849.2M | ||
| Q2 25 | $481.9M | $882.3M | ||
| Q1 25 | $479.9M | $820.8M | ||
| Q4 24 | $448.9M | $906.9M | ||
| Q3 24 | $425.4M | $878.9M | ||
| Q2 24 | $418.0M | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $1.3B | $2.5B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.2B | $2.5B | ||
| Q4 24 | $1.3B | $2.5B | ||
| Q3 24 | $1.1B | $2.5B | ||
| Q2 24 | $1.1B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | 0.73× | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | 1.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $79.7M | $293.2M |
| Free Cash FlowOCF − Capex | $50.3M | $209.9M |
| FCF MarginFCF / Revenue | 19.6% | 60.6% |
| Capex IntensityCapex / Revenue | 11.5% | 9.5% |
| Cash ConversionOCF / Net Profit | 6.31× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $99.5M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $79.7M | $93.6M | ||
| Q3 25 | $49.2M | $111.3M | ||
| Q2 25 | $56.9M | $17.4M | ||
| Q1 25 | $60.9M | $116.6M | ||
| Q4 24 | $-13.5M | $43.8M | ||
| Q3 24 | $26.8M | $48.8M | ||
| Q2 24 | $18.4M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $50.3M | $87.2M | ||
| Q3 25 | $13.2M | $106.3M | ||
| Q2 25 | $-3.7M | $13.6M | ||
| Q1 25 | $39.6M | $100.9M | ||
| Q4 24 | $-36.1M | $35.2M | ||
| Q3 24 | $-11.5M | $39.4M | ||
| Q2 24 | $-34.0M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | 19.6% | 25.7% | ||
| Q3 25 | 6.8% | 32.5% | ||
| Q2 25 | -1.9% | 4.2% | ||
| Q1 25 | 16.3% | 30.5% | ||
| Q4 24 | -17.8% | 10.1% | ||
| Q3 24 | -6.0% | 11.4% | ||
| Q2 24 | -20.0% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 11.5% | 1.9% | ||
| Q3 25 | 18.4% | 1.5% | ||
| Q2 25 | 31.3% | 1.2% | ||
| Q1 25 | 8.7% | 4.7% | ||
| Q4 24 | 11.2% | 2.5% | ||
| Q3 24 | 20.0% | 2.7% | ||
| Q2 24 | 30.8% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | 6.31× | 2.09× | ||
| Q3 25 | 2.77× | 2.88× | ||
| Q2 25 | 5.87× | 0.51× | ||
| Q1 25 | 1.82× | 2.01× | ||
| Q4 24 | -0.69× | 1.17× | ||
| Q3 24 | 3.02× | 1.44× | ||
| Q2 24 | 2.39× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GLDD
Segment breakdown not available.
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
